Treatment of cervical dystonia with botulinum toxin
Identifieur interne : 003B01 ( Main/Exploration ); précédent : 003B00; suivant : 003B02Treatment of cervical dystonia with botulinum toxin
Auteurs : Joseph Jankovic [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Anti-Dyskinesia Agents (immunology), Anti-Dyskinesia Agents (therapeutic use), Bontoxilysin, Botulinum Toxins (immunology), Botulinum Toxins (therapeutic use), Clinical Trials as Topic (methods), Double-Blind Method, Dystonia, Humans, Nervous system diseases, Time Factors, Torticollis (drug therapy), Treatment, botulinum toxin, cervical dystonia, dystonia.
- MESH :
- chemical , immunology : Anti-Dyskinesia Agents, Botulinum Toxins.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug therapy : Torticollis.
- methods : Clinical Trials as Topic.
- Double-Blind Method, Humans, Time Factors.
Abstract
Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20024
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000D34
- to stream Istex, to step Curation: 000D34
- to stream Istex, to step Checkpoint: 002482
- to stream PubMed, to step Corpus: 003505
- to stream PubMed, to step Curation: 003505
- to stream PubMed, to step Checkpoint: 003277
- to stream Ncbi, to step Merge: 000D79
- to stream Ncbi, to step Curation: 000D79
- to stream Ncbi, to step Checkpoint: 000D79
- to stream Main, to step Merge: 005459
- to stream PascalFrancis, to step Corpus: 002236
- to stream PascalFrancis, to step Curation: 000A85
- to stream PascalFrancis, to step Checkpoint: 001F74
- to stream Main, to step Merge: 005812
- to stream Main, to step Curation: 003B01
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of cervical dystonia with botulinum toxin</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20024</idno><idno type="url">https://api.istex.fr/document/A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D34</idno><idno type="wicri:Area/Istex/Curation">000D34</idno><idno type="wicri:Area/Istex/Checkpoint">002482</idno><idno type="wicri:doubleKey">0885-3185:2004:Jankovic J:treatment:of:cervical</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15027062</idno><idno type="wicri:Area/PubMed/Corpus">003505</idno><idno type="wicri:Area/PubMed/Curation">003505</idno><idno type="wicri:Area/PubMed/Checkpoint">003277</idno><idno type="wicri:Area/Ncbi/Merge">000D79</idno><idno type="wicri:Area/Ncbi/Curation">000D79</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D79</idno><idno type="wicri:doubleKey">0885-3185:2004:Jankovic J:treatment:of:cervical</idno><idno type="wicri:Area/Main/Merge">005459</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0228898</idno><idno type="wicri:Area/PascalFrancis/Corpus">002236</idno><idno type="wicri:Area/PascalFrancis/Curation">000A85</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001F74</idno><idno type="wicri:doubleKey">0885-3185:2004:Jankovic J:treatment:of:cervical</idno><idno type="wicri:Area/Main/Merge">005812</idno><idno type="wicri:Area/Main/Curation">003B01</idno><idno type="wicri:Area/Main/Exploration">003B01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of cervical dystonia with botulinum toxin</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03">2004-03</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S109">S109</biblScope><biblScope unit="page" to="S115">S115</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C</idno><idno type="DOI">10.1002/mds.20024</idno><idno type="ArticleID">MDS20024</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Dyskinesia Agents (immunology)</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Bontoxilysin</term><term>Botulinum Toxins (immunology)</term><term>Botulinum Toxins (therapeutic use)</term><term>Clinical Trials as Topic (methods)</term><term>Double-Blind Method</term><term>Dystonia</term><term>Humans</term><term>Nervous system diseases</term><term>Time Factors</term><term>Torticollis (drug therapy)</term><term>Treatment</term><term>botulinum toxin</term><term>cervical dystonia</term><term>dystonia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Humans</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Dystonie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cervical dystonia (CD) is the most common form of dystonia encountered in a movement disorders clinic. The treatment of this focal dystonia has improved markedly with the advent on botulinum toxin (BTX) injections, which has now become the treatment of choice. Initial studies, even double‐blind controlled trials, failed to show robust effect, largely as a result of poor design, often using fixed dosage and site of administration. When the BTX treatment is customized to the needs of the individual patients and the most involved muscles are targeted, the effects can be quite dramatic and the improvement usually lasts 3 to 4 months. Experience and improved skills can largely prevent the adverse effects such as dysphagia and neck weakness. Although there is no evidence that BTX slows the progression of the disease, as a result of early intervention with BTX, many of the long‐term complications of CD, such as contractures and radiculopathy, have been largely eliminated. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A649C82B7FE863ACAFD9A07C88CC08BA5E41FB4C
|texte= Treatment of cervical dystonia with botulinum toxin
}}
| This area was generated with Dilib version V0.6.23. |  |